Please login to the form below
celecoxib
This page shows the latest celecoxib news and features for those working in and with pharma, biotech and healthcare.
Products over pipeline in Pfizer's acquisition targets, hints CEO
Most damaging to Pfizer's top-line this year was the loss of patent protection for big-selling painkiller Celebrex (celecoxib) last December in the US, with competition already being felt
Latest news
-
Pfizer 2014 guidance threatened by Celebrex competition
courts. Several generic pharma companies have been planning to launch copycat versions of Celebrex (celecoxib) in the US on May 30, when the basic patent on the active ingredient of the
-
Pfizer sales down but oncology shows promise
There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a
-
Pfizer sales dip as net income surges in Q2
Epilepsy, neuropathic pain and fibromyalgia therapy Lyrica (pregabalin) cemented its position as Pfizer's biggest product with a 10 per cent gain to $1.13bn, while painkiller Celebrex (celecoxib) grew 10
-
GSK fires senior Chinese scientist over data fabrication
to faking dozens of research studies, including trials of Pfizer's Celebrex (celecoxib) and Merck &Co's Vioxx (rofecoxib).
-
Pfizer sues as Celebrex patent is reissued in US
Celebrex (celecoxib) remains a major product for Pfizer, with global sales growing 9 per cent to $2.7bn last year, mainly as a treatment for osteoarthritis. ... We are pleased with the reissuance of this patent protecting the invention of using celecoxib
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Immunocore names CEO
During this time he helped bring several drugs to markets including Celebrex (celecoxib) and Relpax (eletriptan) and to establish the company in India and China.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
